## BRAWN PHARMACEUTICALS LIMITED REGD. OFFICE: C-64, LAJPAT NAGAR,-1, NEW DELHI-110024

## AUDITED FINANCIAL RESULTS FOR THE QUARTER/YEAR ENDED 31ST MARCH 2009

Particulars			(Rs. In Lacs)	
	Quarter Ended	Quarter Ended	Year Ended	Year Ended
	31.3.2009	31.3.2008	31.3.2009	31.3.2008
1. (a) Net Sales/ Income from		10.07		
Operations	135.32	16.35	409.94	92.66
2. Expenditure				
a. Increse/decrease in stock in trade and work in progress	-	-	-	-
b. Consumptin of raw materials	-	-	-	-
c. Purchase of traded goods	96.93	6.08	333.85	74.32
d. Employee cost	5.51	1.50	19.26	6.23
e. Depreciation	0.04	-	0.09	-
f. Other Expenditure	4.15	2.22	15.31	4.11
g. Total	106.63	9.80	368.51	84.66
3. Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	28.69	6.55	41.43	8.00
4. Other Income	20.03	0.00	41.45	0.00
5. Profit before Interest and Exceptional Items (3+4)			-	
6. Interest	28.69	6.55	41.43	8.00
	-	-	0.02	-
7. Profit after Interest but before Exceptional Items (5-6)	28.69	6.55	41.41	8.00
8. Exceptional items	-	-	-	-
9. Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	28.69	6.55	41.41	8.00
10. Tax Expenses (Provisions)	4.39	0.34	4.39	0.34
<ol> <li>Net Profit (+)/ Loss (-) from</li> <li>Ordinary Activities after tax (9-</li> <li>10)</li> </ol>	24.30	6.21	37.02	7.66
12. Extraordinary Item	-	-	-	-
13. Net Profit(+)/ Loss(-) for the period (11-12)	24.30	6.21	37.02	7.66
14. Excess Provision for Income Tax of P.Y. W/back	-	0.13		0.13
15. Provision for Gratuity	0.24	0.01	0.24	0.01
16. Provision for Deferred Tax Adjustments	-	(6.84)	-	(6.84)
17. Net Profit(+)/Loss(-) after tax	24.06	(0.51)	36.78	0.94
18. Paid-up equity share capital (Face Value of the Share is		· · · · ·		
Rs.10/- each)	300.03	300.03	300.03	300.03

19. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	46.62	9.60	46.62	9.60
20. Earnings Per Share (EPS)	0.08	0.02	0.12	0.03
21. Public Shareholding		0.01	0	
- No. of shares	1,713,250	1,713,250	1,713,250	1,713,250
- Percentage of shareholding	57.10	57.10	57.10	57.10
22. Promoters and promoter group Shareholding				
a) Pledged/Encumbered	Nil	Nil	Nil	Nil
b) Non-encumbered				
<ul> <li>Number of Shares</li> <li>Percentage of shares (as a% of the total shareholding of</li> </ul>	1,287,050	1,287,050	1,287,050	1,287,050
promoter and promoter group)	42.90	42.90	42.90	42.90

Notes: 1- The above financial results have been taken on record by the board of the directors at their meeting held on 20.06.2009.

2- Segment reporting as defined in Accounting Standard-17 is not applicable to the company.

3- Summary of Investor's Complaints: Opening: Nil, Received during the quarter: Nil, Resolved: Nil, Closing: Nil.

For and on behalf of Brawn Pharmaceuticals Limited

Place: New Delhi Date: 20.06.2009 Sd/-Chief Accounts Officer Sd/-Managing Director